Calamos Advisors LLC Makes New Investment in Xeris Biopharma Holdings, Inc. $XERS

Calamos Advisors LLC bought a new stake in shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund bought 137,097 shares of the company’s stock, valued at approximately $1,116,000. Calamos Advisors LLC owned approximately 0.08% of Xeris Biopharma at the end of the most recent reporting period.

A number of other hedge funds have also recently added to or reduced their stakes in the company. Tower Research Capital LLC TRC grew its position in Xeris Biopharma by 913.1% during the second quarter. Tower Research Capital LLC TRC now owns 17,395 shares of the company’s stock valued at $81,000 after buying an additional 15,678 shares during the period. Modern Wealth Management LLC purchased a new stake in shares of Xeris Biopharma during the 2nd quarter worth about $83,000. Los Angeles Capital Management LLC purchased a new stake in shares of Xeris Biopharma during the 2nd quarter worth about $95,000. Acadian Asset Management LLC acquired a new stake in shares of Xeris Biopharma during the 1st quarter valued at about $96,000. Finally, Nebula Research & Development LLC purchased a new position in shares of Xeris Biopharma in the 2nd quarter valued at about $97,000. 42.75% of the stock is owned by hedge funds and other institutional investors.

Xeris Biopharma Trading Up 7.4%

XERS opened at $7.85 on Friday. Xeris Biopharma Holdings, Inc. has a twelve month low of $3.14 and a twelve month high of $10.08. The firm has a market capitalization of $1.30 billion, a PE ratio of -78.49 and a beta of 0.50. The firm’s 50-day moving average price is $7.61 and its 200 day moving average price is $7.04.

Xeris Biopharma (NASDAQ:XERS) last released its earnings results on Thursday, November 6th. The company reported $0.00 earnings per share for the quarter, missing analysts’ consensus estimates of $0.01 by ($0.01). The business had revenue of $74.38 million for the quarter, compared to analyst estimates of $74.19 million. As a group, analysts predict that Xeris Biopharma Holdings, Inc. will post -0.41 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, Director Barbara-Jean A. Bormann-Kennedy sold 15,000 shares of Xeris Biopharma stock in a transaction on Friday, December 12th. The stock was sold at an average price of $7.09, for a total transaction of $106,350.00. Following the transaction, the director owned 142,500 shares in the company, valued at $1,010,325. The trade was a 9.52% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, Director John Johnson sold 135,400 shares of the business’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $7.22, for a total transaction of $977,588.00. Following the transaction, the director directly owned 698,083 shares in the company, valued at approximately $5,040,159.26. The trade was a 16.25% decrease in their position. The SEC filing for this sale provides additional information. In the last ninety days, insiders have sold 206,976 shares of company stock worth $1,497,495. 6.47% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

XERS has been the topic of a number of recent analyst reports. Weiss Ratings reiterated a “sell (d-)” rating on shares of Xeris Biopharma in a research report on Wednesday, October 8th. Wall Street Zen downgraded Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research note on Saturday, November 8th. Zacks Research lowered Xeris Biopharma from a “strong-buy” rating to a “hold” rating in a research report on Thursday, October 30th. Oppenheimer reissued an “outperform” rating and issued a $18.00 price target on shares of Xeris Biopharma in a report on Friday, November 7th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Xeris Biopharma in a report on Friday, November 7th. Six research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average target price of $9.50.

About Xeris Biopharma

Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas.

The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S.